PatientSpotlight, by PanaceaIntelPatientSpotlight

Topic · Rare Disease

Policy

Coverage of policy decisions shaping care - Medicare and CMS, NICE and other HTA bodies, and the broader public-policy frame around chronic disease. 2 pieces on policy in Rare Disease, newest first within each collection.

← All topics
FilterAll (16)Rare Disease (2)Immunology (1)Neurology (11)Cardiometabolic (1)Respiratory (1)

Signals

2
SignalApr 26, 2026regulatory-body

UK newborn screening expansion proposal would change the rare-disease patient-finding model

The UK National Screening Committee's proposed expansion of the newborn blood-spot screening panel to additional rare conditions has implications for diagnosis timing, treatment-eligible patient identification, and commercial planning for orphan therapies in those conditions.

PolicyDiagnosis
SignalApr 26, 2026NICE

NICE rare-disease modifier consultation is reshaping HTA for ultra-rare therapies

NICE's consultation on the severity modifier and the rare-disease threshold has substantive implications for ultra-rare therapy access in England. The submitted consultation responses are diverging on the question of whether the threshold should be retained, reframed or removed.

Market accessPolicyRegulatory